(News Bulletin 247) – Innate Pharma announced today that the abstract entitled ‘A first-in-human study of CD123 NK Cell Engager SAR443579 in relapsed or refractory acute myeloid leukemia, B-cell acute lymphoblastic leukemia or high risk-myelodysplasia ‘ was published on the American Society for Clinical Oncology (ASCO) 2023 Annual Meeting website.
This study summary concludes that SAR’579, developed by Sanofi, was well tolerated up to a dose of 3mg/kg weekly and clinical benefit was observed in patients with relapsed or refractory acute myeloid leukemia .
‘We are pleased to see the first clinical responses and good tolerability of SAR’579/IPH6101 in the dose escalation of this Phase 1/2 study in patients with relapsed or refractory acute myeloid leukemia (AML) ,’ comments Mondher Mahjoubi, Chairman of the Management Board of Innate Pharma.
Data from this Phase 1/2 will be presented in an oral presentation at the ASCO 2023 Annual Meeting. The study is progressing to the dose extension phase.
Copyright (c) 2023 News Bulletin 247. All rights reserved.
I have over 8 years of experience working in the news industry. I have worked as a reporter, editor, and now managing editor at 247 News Agency. I am responsible for the day-to-day operations of the news website and overseeing all of the content that is published. I also write a column for the website, covering mostly market news.
